Infectious Diseases

The Infectious Disease (ID) Group seeks to develop more effective treatments for viral infections through a better understanding of the mechanism of viral replication. Using innovative approaches, the group targets both host and viral factors.

Using a combination of innovative approaches and fundamental research into the mechanisms of bacterial drug resistance, the group is developing new classes of antibacterial agents with novel mechanisms of action to address this growing medical need.

The ID Group concentrates on viral infections such as the hepatitis C virus, the respiratory syncytial virus, and human cytomegalovirus, as well as multi-resistant bacterial infections such as clostridium difficile, staphylococcus aureus, and gram-negative pathogens.

 

 

Selected publications

• Mathy J.E.; Ma S.; Compton T.; Lin K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. (Sep, 2008); 52(9):3267-75. Epub Jun 30, 2008.
• Projan S.J.(Genome) size matters.   Antimicrob Agents Chemother. (Apr, 2007);51(4): 1133-4. Epub Feb 12, 2007.
• Dean C.R.; Narayan S.; Richards J.; Daigle D.M.; Esterow S.; Leeds J.A.; Kamp H.; Puyang X.; Wiedmann B.; Mueller D.; Voshol H.; van Oostrum J.; Wall D.; Koehn J.; Dzink-Fox J.; Ryder N.S. Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number. Antimicrob Agents Chemother. (2007); 51: 1004-1010.